Rapport Therapeutics Common Stock Statistics Share Statistics Rapport Therapeutics Common Stock has 36.5M
shares outstanding. The number of shares has increased by -0.22%
in one year.
Shares Outstanding 36.5M Shares Change (YoY) -0.22% Shares Change (QoQ) 0% Owned by Institutions (%) 8.45% Shares Floating 17.45M Failed to Deliver (FTD) Shares 11,740 FTD / Avg. Volume 6.42%
Short Selling Information The latest short interest is 2.86M, so 7.84% of the outstanding
shares have been sold short.
Short Interest 2.86M Short % of Shares Out 7.84% Short % of Float 19.03% Short Ratio (days to cover) 16.89
Valuation Ratios The PE ratio is -46.98 and the forward
PE ratio is -3.51.
Rapport Therapeutics Common Stock's PEG ratio is
-0.47.
PE Ratio -46.98 Forward PE -3.51 PS Ratio 0 Forward PS n/a PB Ratio 12.05 P/FCF Ratio -54.72 PEG Ratio -0.47
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Rapport Therapeutics Common Stock.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 35.34,
with a Debt / Equity ratio of 0.
Current Ratio 35.34 Quick Ratio 35.34 Debt / Equity 0 Debt / EBITDA -0.02 Debt / FCF -0.02 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.13M Employee Count 69 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -21.35% in the
last 52 weeks. The beta is 0.64, so Rapport Therapeutics Common Stock's
price volatility has been higher than the market average.
Beta 0.64 52-Week Price Change -21.35% 50-Day Moving Average 13.09 200-Day Moving Average 14.72 Relative Strength Index (RSI) 51.76 Average Volume (20 Days) 182,919
Income Statement
Revenue n/a Gross Profit n/a Operating Income -83.06M Net Income -78.31M EBITDA -77.47M EBIT -78.31M Earnings Per Share (EPS) -0.38
Full Income Statement Balance Sheet The company has 56.8M in cash and 1.48M in
debt, giving a net cash position of 55.33M.
Cash & Cash Equivalents 56.8M Total Debt 1.48M Net Cash 55.33M Retained Earnings -123.75M Total Assets 302.05M Working Capital 281.58M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -64.83M
and capital expenditures -2.4M, giving a free cash flow of -67.23M.
Operating Cash Flow -64.83M Capital Expenditures -2.4M Free Cash Flow -67.23M FCF Per Share -0.32
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
